X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Biocon Ltd with Strides Arcolab - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON LTD vs STRIDES SHASUN LTD - Comparison Results

BIOCON LTD    Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

STRIDES SHASUN LTD 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON LTD STRIDES SHASUN LTD BIOCON LTD/
STRIDES SHASUN LTD
 
P/E (TTM) x 82.9 13.2 630.0% View Chart
P/BV x 7.8 1.5 511.6% View Chart
Dividend Yield % 0.2 0.6 24.5%  

Financials

 BIOCON LTD   STRIDES SHASUN LTD
EQUITY SHARE DATA
    BIOCON LTD
Mar-17
STRIDES SHASUN LTD
Mar-17
BIOCON LTD/
STRIDES SHASUN LTD
5-Yr Chart
Click to enlarge
High Rs1,1621,275 91.2%   
Low Rs483918 52.6%   
Sales per share (Unadj.) Rs194.6389.6 49.9%  
Earnings per share (Unadj.) Rs34.428.0 123.0%  
Cash flow per share (Unadj.) Rs48.348.9 98.7%  
Dividends per share (Unadj.) Rs1.004.50 22.2%  
Dividend yield (eoy) %0.10.4 29.6%  
Book value per share (Unadj.) Rs241.9303.1 79.8%  
Shares outstanding (eoy) m200.0089.42 223.7%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.22.8 150.2%   
Avg P/E ratio x23.939.2 61.0%  
P/CF ratio (eoy) x17.022.4 76.0%  
Price / Book Value ratio x3.43.6 94.0%  
Dividend payout %2.916.1 18.1%   
Avg Mkt Cap Rs m164,44098,036 167.7%   
No. of employees `0009.25.8 159.2%   
Total wages/salary Rs m7,4705,881 127.0%   
Avg. sales/employee Rs Th4,213.96,005.9 70.2%   
Avg. wages/employee Rs Th809.01,014.0 79.8%   
Avg. net profit/employee Rs Th745.2431.2 172.8%   
INCOME DATA
Net Sales Rs m38,91134,834 111.7%  
Other income Rs m1,5711,686 93.2%   
Total revenues Rs m40,48236,520 110.8%   
Gross profit Rs m9,7956,428 152.4%  
Depreciation Rs m2,7721,872 148.1%   
Interest Rs m2602,269 11.5%   
Profit before tax Rs m8,3343,973 209.8%   
Minority Interest Rs m1630-   
Prior Period Items Rs m04 0.0%   
Extraordinary Inc (Exp) Rs m0-1,006 0.0%   
Tax Rs m1,616470 343.8%   
Profit after tax Rs m6,8812,501 275.1%  
Gross profit margin %25.218.5 136.4%  
Effective tax rate %19.411.8 163.9%   
Net profit margin %17.77.2 246.3%  
BALANCE SHEET DATA
Current assets Rs m40,47738,165 106.1%   
Current liabilities Rs m16,78330,402 55.2%   
Net working cap to sales %60.922.3 273.2%  
Current ratio x2.41.3 192.1%  
Inventory Days Days6077 77.1%  
Debtors Days Days83104 79.3%  
Net fixed assets Rs m45,07337,639 119.8%   
Share capital Rs m1,000894 111.8%   
"Free" reserves Rs m47,37726,210 180.8%   
Net worth Rs m48,37727,105 178.5%   
Long term debt Rs m21,08216,377 128.7%   
Total assets Rs m93,94281,168 115.7%  
Interest coverage x33.12.8 1,201.6%   
Debt to equity ratio x0.40.6 72.1%  
Sales to assets ratio x0.40.4 96.5%   
Return on assets %7.65.9 129.3%  
Return on equity %14.29.2 154.2%  
Return on capital %12.612.1 104.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m12,98813,465 96.5%   
Fx outflow Rs m7,8994,076 193.8%   
Net fx Rs m5,0899,389 54.2%   
CASH FLOW
From Operations Rs m6,4002,881 222.1%  
From Investments Rs m-4,985-7,051 70.7%  
From Financial Activity Rs m-1,7753,382 -52.5%  
Net Cashflow Rs m-473-788 60.1%  

Share Holding

Indian Promoters % 40.4 27.7 145.8%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 37.8 22.2%  
FIIs % 10.7 8.6 124.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 25.9 76.8%  
Shareholders   109,995 56,241 195.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON LTD With:   ALEMBIC PHARMA  DISHMAN PHARMA  J.B.CHEMICALS  ASTRAZENECA PHARMA  DIVIS LABORATORIES  

Compare BIOCON LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON LTD SHARE PRICE


Feb 23, 2018 (Close)

TRACK BIOCON LTD

  • Track your investment in BIOCON LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

BIOCON LTD - SUVEN LIFE COMPARISON

COMPARE BIOCON LTD WITH

MARKET STATS